TABLE 3.
The discriminative ability of serological biomarkers with regard to disease behaviour subtypes in patients with Crohn's disease
| Biomarker | Unadjusted | Adjusted (full model) a | Adjusted (residual marker value) b | |||
|---|---|---|---|---|---|---|
| Non‐penetrating, non‐stricturing CD (Montreal B1) versus stricturing CD (Montreal B2) | ||||||
| AUC (95% CI) | Nominal p‐value | AUC (95% CI) | p‐value | AUC (95% CI) | p‐value | |
| C1M | 0.69 (0.56–0.83) | 0.009 | 0.91 (0.84–0.98) | <0.001 | 0.78 (0.67–0.89) | <0.001 |
| C3M | 0.66 (0.53–0.80) | 0.028 | 0.92 (0.84–0.99) | <0.001 | 0.91 (0.83–0.98) | <0.001 |
| PRO‐C3 | 0.52 (0.38–0.67) | 0.760 | ||||
| C3M/PRO‐C3 | 0.61 (0.47–0.75) | 0.126 | ||||
| C4M | 0.68 (0.55–0.82) | 0.013 | 0.92 (0.85–0.99) | <0.001 | 0.87 (0.79–0.96) | <0.001 |
| PRO‐C4 | 0.57 (0.42–0.71) | 0.359 | ||||
| PRO‐C4/C4M | 0.71 (0.57–0.84) | 0.005 | 0.92 (0.85–0.99) | <0.001 | 0.90 (0.82–0.98) | <0.001 |
| C4G | 0.50 (0.36–0.65) | 0.962 | ||||
| C6Ma3 | 0.59 (0.44–0.73) | 0.234 | ||||
| Biomarker | Unadjusted | Adjusted (full model) b | Adjusted (residual marker value) b | |||
|---|---|---|---|---|---|---|
| Non‐penetrating, non‐stricturing CD (Montreal B1) versus penetrating CD (Montreal B3) | ||||||
| AUC (95% CI) | Nominal p‐value | AUC (95% CI) | p‐value | AUC (95% CI) | p‐value | |
| C1M | 0.51 (0.38–0.64) | 0.877 | ||||
| C3M | 0.52 (0.39–0.65) | 0.775 | ||||
| PRO‐C3 | 0.58 (0.45–0.71) | 0.232 | ||||
| C3M/PRO‐C3 | 0.58 (0.45–0.71) | 0.236 | ||||
| C4M | 0.52 (0.39–0.65) | 0.791 | ||||
| PRO‐C4 | 0.56 (0.42–0.69) | 0.414 | ||||
| PRO‐C4/C4M | 0.64 (0.51–0.76) | 0.043 | 0.87 (0.79–0.96) | <0.001 | 0.87 (0.79–0.96) | <0.001 |
| C4G | 0.55 (0.42–0.69) | 0.433 | ||||
| C6Ma3 | 0.51 (0.37–0.64) | 0.935 | ||||
| Biomarker | Unadjusted | Adjusted (full model) d | Adjusted (residual marker value) b | |||
|---|---|---|---|---|---|---|
| Stricturing CD (Montreal B2) versus penetrating CD (Montreal B3) | ||||||
| AUC (95% CI) | Nominal p‐value | AUC (95% CI) | p‐value | AUC (95% CI) | p‐value | |
| C1M | 0.70 (0.56–0.83) | 0.008 | 0.81 (0.70–0.92) | <0.001 | 0.81 (0.70–0.92) | <0.001 |
| C3M | 0.65 (0.51–0.78) | 0.048 | 0.80 (0.68–0.91) | <0.001 | 0.80 (0.68–0.91) | <0.001 |
| PRO‐C3 | 0.58 (0.43–0.72) | 0.289 | ||||
| C3M/PRO‐C3 | 0.54 (0.39–0.68) | 0.610 | ||||
| C4M | 0.67 (0.53–0.80) | 0.023 | 0.81 (0.70–0.92) | <0.001 | 0.81 (0.70–0.92) | <0.001 |
| PRO‐C4 | 0.61 (0.47–0.75) | 0.137 | ||||
| PRO‐C4/C4M | 0.59 (0.44–0.73) | 0.251 | ||||
| C4G | 0.56 (0.42–0.70) | 0.411 | ||||
| C6Ma3 | 0.59 (0.45–0.74) | 0.204 | ||||
a
Adjusted for history of ileocecal resection, concurrent use of immunosuppressives and platelet counts (derived from multivariable backwards logistic regression analysis containing these confounding factors).
b
Adjusted for unstandardized residual value of the biomarker (derived from linear regression analysis, adjusted for the same confounders) to the determine the prognostic value of the biomarker only.
c
Adjusted for perianal disease and history of ileocaecal resection.
d
Adjusted for perianal disease.